| Primary |
| Product Used For Unknown Indication |
65.4% |
| Epilepsy |
15.0% |
| Maternal Exposure Timing Unspecified |
6.7% |
| Bipolar Disorder |
1.4% |
| Depression |
1.4% |
| Convulsion |
0.9% |
| Drug Abuse |
0.9% |
| Intentional Self-injury |
0.9% |
| Mental Disorder |
0.9% |
| Prophylaxis |
0.9% |
| Paranoid Personality Disorder |
0.7% |
| Type 2 Diabetes Mellitus |
0.7% |
| Encephalitis |
0.5% |
| Epilepsy Congenital |
0.5% |
| Personality Disorder |
0.5% |
| Schizophrenia |
0.5% |
| Sepsis |
0.5% |
| Status Epilepticus |
0.5% |
| Abnormal Behaviour |
0.4% |
| Cardiac Failure Congestive |
0.4% |
|
| Vomiting |
12.3% |
| Somnolence |
9.6% |
| Trismus |
9.6% |
| Foetal Exposure During Pregnancy |
8.2% |
| Thrombocytopenia |
6.8% |
| Epilepsy |
5.5% |
| Foaming At Mouth |
4.1% |
| Grand Mal Convulsion |
4.1% |
| Inappropriate Antidiuretic Hormone Secretion |
4.1% |
| Loss Of Consciousness |
4.1% |
| Rash |
4.1% |
| Speech Disorder |
4.1% |
| Tremor |
4.1% |
| Hepatic Fibrosis |
2.7% |
| Hepatic Function Abnormal |
2.7% |
| Hyperammonaemia |
2.7% |
| Pleurisy |
2.7% |
| Skin Exfoliation |
2.7% |
| Spina Bifida |
2.7% |
| Status Epilepticus |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
41.7% |
| Epilepsy |
29.2% |
| Bipolar Disorder |
12.4% |
| Pneumonia |
2.7% |
| Sedation |
2.2% |
| Bipolar I Disorder |
1.6% |
| Drug Exposure In Utero |
1.1% |
| Salivary Hypersecretion |
1.0% |
| Diarrhoea |
0.8% |
| Pain |
0.8% |
| Psychotic Disorder |
0.8% |
| Breast Cancer |
0.6% |
| Depression |
0.6% |
| Drug Exposure Via Mother |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Hypertension |
0.6% |
| Hypothyroidism |
0.6% |
| Myelodysplastic Syndrome |
0.6% |
| Myoclonic Epilepsy |
0.6% |
| Prophylaxis |
0.6% |
|
| Vomiting |
17.5% |
| Trismus |
8.7% |
| Cardiac Failure |
6.8% |
| Neutropenia |
6.8% |
| Thrombocytopenia |
6.8% |
| Loss Of Consciousness |
5.8% |
| Urinary Retention |
5.8% |
| Gingival Hyperplasia |
3.9% |
| Grand Mal Convulsion |
3.9% |
| Off Label Use |
3.9% |
| Somnolence |
3.9% |
| Transaminases |
3.9% |
| Transaminases Increased |
3.9% |
| Epilepsy |
2.9% |
| Exposure During Pregnancy |
2.9% |
| Rash Pustular |
2.9% |
| Respiratory Distress |
2.9% |
| Toxic Epidermal Necrolysis |
2.9% |
| Hepatitis Acute |
1.9% |
| Hyporeflexia |
1.9% |
|
| Concomitant |
| Epilepsy |
25.9% |
| Product Used For Unknown Indication |
20.0% |
| Convulsion |
5.2% |
| Partial Seizures |
5.0% |
| Schizophrenia |
4.3% |
| Colorectal Cancer Metastatic |
4.0% |
| Drug Use For Unknown Indication |
4.0% |
| Bipolar I Disorder |
3.1% |
| Diabetes Mellitus |
2.9% |
| Hypertension |
2.9% |
| Mantle Cell Lymphoma |
2.9% |
| Breast Cancer |
2.6% |
| Infantile Spasms |
2.6% |
| Hiv Infection |
2.4% |
| Pain |
2.4% |
| Primary Hypothyroidism |
2.1% |
| Rheumatoid Arthritis |
2.1% |
| Asthma |
1.9% |
| Depression |
1.9% |
| Schizophrenia, Paranoid Type |
1.9% |
|
| Epilepsy |
14.1% |
| Somnolence |
10.9% |
| Weight Decreased |
9.4% |
| Convulsion |
7.8% |
| Pancytopenia |
6.3% |
| Cardiac Disorder |
4.7% |
| Deep Vein Thrombosis |
4.7% |
| Septic Shock |
4.7% |
| Completed Suicide |
3.1% |
| Fatigue |
3.1% |
| Febrile Bone Marrow Aplasia |
3.1% |
| Female Orgasmic Disorder |
3.1% |
| Hypertonia |
3.1% |
| Ileus |
3.1% |
| Neurodermatitis |
3.1% |
| Off Label Use |
3.1% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.1% |
| Prescribed Overdose |
3.1% |
| Psychotic Disorder |
3.1% |
| Rash Generalised |
3.1% |
|
| Interacting |
| Idiopathic Generalised Epilepsy |
19.0% |
| Anxiety |
14.3% |
| Epilepsy |
14.3% |
| Antiinflammatory Therapy |
9.5% |
| Arthralgia |
9.5% |
| Bipolar I Disorder |
9.5% |
| Paraneoplastic Syndrome |
9.5% |
| Affective Disorder |
4.8% |
| Depression |
4.8% |
| Insomnia |
4.8% |
|
| Hyperammonaemia |
33.3% |
| Status Epilepticus |
22.2% |
| Toxicity To Various Agents |
22.2% |
| Off Label Use |
11.1% |
| Septic Shock |
11.1% |
|
